Expert Interview
Discussing Roche Genentech's topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis.
Ticker(s): RHHBFInstitution: Mass General | Harvard
- Clinical researcher & clinician in academic nephrology practice; Nephrologist at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School.
- Currently manages 8-10 patients with CKD associated pruritus, and 6 patients with C3 glomerulopathy.
- Conducts patient-oriented research in the areas of calciphylaxis, vascular calcification and hyponatremia, has authored over 50 peer-reviewed research articles, and research is funded by organizations including the American Kidney Fund & the National Kidney Foundation.
What is your professional background and current clinical practice, and what volume of lupus patients do you see monthly?
Can you provide an overview of the unmet need in lupus nephritis??
What are your thoughts on the recent results from the REGENCY study of Gazyva?
How does Obinutuzumab (Gazyva) compare to Rituximab in terms of efficacy and safety for lupus nephritis, and why might it be preferred over Rituximab?
Added By: catalin_adminHow does the response rate and potential benefit of Obinutuzumab compare to current first and second-line therapies like Belimumab and Voclosporin?
Added By: catalin_adminWhat are your thoughts on the significance of secondary endpoints from the REGENCY study, including reduced corticosteroid use and proteinuria reduction, and how important are these outcomes for patient treatment?
Added By: catalin_adminCould future B-cell depletion therapies, such as CAR T-cell treatments or T-cell engagers like CD20xCD3 bispecific antibodies, potentially outperform Obinutuzumab in lupus nephritis?
Added By: catalin_adminHow do you assess the overall safety profile of Obinutuzumab in lupus nephritis, especially given the existing data from its use in other conditions, and are there any notable risks or limitations?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
